Single doses of up to 640mg given both intravenously and subcutaneously have been administered in clinical studies without evidence of dose-limiting toxicities.L39665 If overdosage of bimekizumab is suspected, monitor the patient for adverse reactions and institute symptomatic treatment as clinically indicated.
Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis.L39665,L39680 It is the first IL-17 inhibitor to target both IL-17A and IL-17F.A244455 It has demonstrated superior efficacy as compared to another IL-17 inhibitor, secukinumab, as well as ustekinumab (an IL-12/23 inhibitor) and adalimumab (a TNF inhibitor) in the treatment of moderate-to-severe psoriasis,A244450,A244455 likely owing to its dual inhibition of both IL-17A and IL-17F. Bimekizumab was also granted FDA approval on October 18, 2023.L48551
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | The metabolism of Diethylstilbestrol can be increased when combined with Bimekizumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Bimekizumab. |
| Conjugated estrogens | The metabolism of Conjugated estrogens can be increased when combined with Bimekizumab. |
| Estrone | Estrone may increase the thrombogenic activities of Bimekizumab. |
| Estradiol | The metabolism of Estradiol can be increased when combined with Bimekizumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Bimekizumab. |
| Ethinylestradiol | The metabolism of Ethinylestradiol can be increased when combined with Bimekizumab. |
| Mestranol | The metabolism of Mestranol can be increased when combined with Bimekizumab. |
| Estriol | Estriol may increase the thrombogenic activities of Bimekizumab. |
| Estrone sulfate | The metabolism of Estrone sulfate can be increased when combined with Bimekizumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Bimekizumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Bimekizumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Bimekizumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Bimekizumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Bimekizumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Bimekizumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Bimekizumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Bimekizumab. |
| Equol | Equol may increase the thrombogenic activities of Bimekizumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Bimekizumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Bimekizumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Bimekizumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Bimekizumab. |
| Estradiol acetate | The metabolism of Estradiol acetate can be increased when combined with Bimekizumab. |
| Estradiol benzoate | The metabolism of Estradiol benzoate can be increased when combined with Bimekizumab. |
| Estradiol cypionate | The metabolism of Estradiol cypionate can be increased when combined with Bimekizumab. |
| Estradiol valerate | The metabolism of Estradiol valerate can be increased when combined with Bimekizumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Bimekizumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Bimekizumab. |
| Estetrol | The metabolism of Estetrol can be increased when combined with Bimekizumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Bimekizumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Bimekizumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Bimekizumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Bimekizumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Bimekizumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bimekizumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Bimekizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Bimekizumab. |
| Trastuzumab | The risk or severity of neutropenia can be increased when Trastuzumab is combined with Bimekizumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Bimekizumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Bimekizumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Bimekizumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Bimekizumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Bimekizumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Bimekizumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bimekizumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Bimekizumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Bimekizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bimekizumab. |
| Natalizumab | The risk or severity of immunosuppression can be increased when Bimekizumab is combined with Natalizumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Bimekizumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Bimekizumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Bimekizumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Bimekizumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Bimekizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Bimekizumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Bimekizumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Bimekizumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Bimekizumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Bimekizumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Bimekizumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Bimekizumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Bimekizumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Bimekizumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Bimekizumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Bimekizumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Bimekizumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Bimekizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Bimekizumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Bimekizumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Bimekizumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Bimekizumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Bimekizumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Bimekizumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Bimekizumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Bimekizumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Bimekizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Bimekizumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Bimekizumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Bimekizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Bimekizumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Bimekizumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Bimekizumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Bimekizumab. |
| Trastuzumab emtansine | The metabolism of Trastuzumab emtansine can be increased when combined with Bimekizumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Bimekizumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Bimekizumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Bimekizumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Bimekizumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Bimekizumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Bimekizumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Bimekizumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Bimekizumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Bimekizumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Bimekizumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Bimekizumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Bimekizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Bimekizumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Bimekizumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Bimekizumab. |